Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sym025 · S095029

Monoclonal antibody · Immune activation, directed at killer cell lectin-like receptor subfamily C member 1 (NKG2A) (KLRC1) · developed by Servier Bio-Innovation LLC

Phase 1/2 Most advanced trial
1 Registered trials

What is Sym025?

Sym025 is a monoclonal antibody that binds the NKG2A receptor on natural killer cells and cytotoxic T lymphocytes, blocking its interaction with HLA-E on tumor cells. This relieves inhibition of these immune cells so they can act against cancer cells. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
S095029
Drug type
Monoclonal antibody
Targets
killer cell lectin-like receptor subfamily C member 1 (NKG2A) (KLRC1), HLA-E (binding partner it blocks)
Mechanism
Immune activation, directed at killer cell lectin-like receptor subfamily C member 1 (NKG2A) (KLRC1)
Pathways
NKG2A/HLA-E inhibitory signaling, NK and CTL cytotoxic activity
Therapy area
Oncology
Developer
Servier Bio-Innovation LLC
In trials of
REGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06162572 Phase 1/2 Non-small Cell Lung Cancer (NSCLC) Active not recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung Cancer (NSCLC)

Other drugs acting on KLRC1

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.